0001415889-22-000714.txt : 20220121
0001415889-22-000714.hdr.sgml : 20220121
20220121204017
ACCESSION NUMBER: 0001415889-22-000714
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220121
FILED AS OF DATE: 20220121
DATE AS OF CHANGE: 20220121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHABER CHRISTOPHER J
CENTRAL INDEX KEY: 0001068029
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14778
FILM NUMBER: 22547249
MAIL ADDRESS:
STREET 1: 29 EMMONS DRIVE
STREET 2: SUITE C-10
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER NAME:
FORMER CONFORMED NAME: SCHABER CHRISTOPHER
DATE OF NAME CHANGE: 19980811
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SOLIGENIX, INC.
CENTRAL INDEX KEY: 0000812796
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 411505029
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 29 EMMONS DRIVE
STREET 2: SUITE B-10
CITY: PRINCETON
STATE: NJ
ZIP: 08540
BUSINESS PHONE: 609-538-8200
MAIL ADDRESS:
STREET 1: 29 EMMONS DRIVE
STREET 2: SUITE B-10
CITY: PRINCETON
STATE: NJ
ZIP: 08540
FORMER COMPANY:
FORMER CONFORMED NAME: DOR BIOPHARMA INC
DATE OF NAME CHANGE: 20020329
FORMER COMPANY:
FORMER CONFORMED NAME: ENDOREX CORP
DATE OF NAME CHANGE: 19960916
FORMER COMPANY:
FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19920703
4
1
form4-01212022_050107.xml
X0306
4
2022-01-21
0000812796
SOLIGENIX, INC.
SNGX
0001068029
SCHABER CHRISTOPHER J
C/O SOLIGENIX, INC.
29 EMMONS DRIVE, SUITE B-10
PRINCETON
NJ
08540
true
true
false
false
CHAIRMAN, CEO AND PRESIDENT
Option (Right to Buy)
0.69
2022-01-21
4
A
0
47315
0
A
2022-01-03
2032-01-02
Common Stock
47315
47315
D
The terms of the stock option provide that it is to vest immediately as to 11,829 shares and to vest as to the remainder at a rate of 2,958 of the shares every three months, beginning on April 3, 2022; provided, however, that, consistent with the 2015 Equity Incentive Plan (the "Plan") and the rules of the Nasdaq Stock Market, such stock option shall not be exercisable nor shall it vest prior to the time when an amendment increasing the number of shares authorized for issuance under the Plan is approved by the stockholders, and provided further that, if such approval has not been obtained within 12 months of the grant date, the stock option shall thereupon be canceled and become null and void. The reporting person voluntarily agreed to cancel the stock option granted January 3, 2022 with respect to 47,315 shares.
/s/ Christopher J. Schaber
2022-01-21